Literature DB >> 16568248

Lipid-lowering drugs.

K Pahan1.   

Abstract

Although a change in life-style is often the method of first choice for lipid lowering, lipid-lowering drugs, in general, help to control elevated levels of different forms of lipids in patients with hyperlipidemia. While one group of drugs, statins, lowers cholesterol, the other group, fibrates, is known to take care of fatty acids and triglycerides. In addition, other drugs, such as ezetimibe, colesevelam, torcetrapib, avasimibe, implitapide, and niacin are also being considered to manage hyperlipidemia. As lipids are very critical for cardiovascular diseases, these drugs reduce fatal and nonfatal cardiovascular abnormalities in the general population. However, a number of recent studies indicate that apart from their lipid-lowering activities, statins and fibrates exhibit multiple functions to modulate intracellular signaling pathways, inhibit inflammation, suppress the production of reactive oxygen species, and modulate T cell activity. Therefore, nowadays, these drugs are being considered as possible therapeutics for several forms of human disorders including cancer, autoimmunity, inflammation, and neurodegeneration. Here I discuss these applications in the light of newly discovered modes of action of these drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16568248      PMCID: PMC1986656          DOI: 10.1007/s00018-005-5406-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  132 in total

Review 1.  Fibrates, dyslipoproteinaemia and cardiovascular disease.

Authors:  G F Watts; S B Dimmitt
Journal:  Curr Opin Lipidol       Date:  1999-12       Impact factor: 4.776

2.  Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1.

Authors:  P Delerive; K De Bosscher; S Besnard; W Vanden Berghe; J M Peters; F J Gonzalez; J C Fruchart; A Tedgui; G Haegeman; B Staels
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

3.  Induction and peroxisomal appearance of gulonolactone oxidase upon clofibrate treatment in mouse liver.

Authors:  L Braun; V Mile; Z Schaff; M Csala; T Kardon; J Mandl; G Bánhegyi
Journal:  FEBS Lett       Date:  1999-09-24       Impact factor: 4.124

Review 4.  Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.

Authors:  D W Bilheimer; S M Grundy; M S Brown; J L Goldstein
Journal:  Trans Assoc Am Physicians       Date:  1983

Review 5.  Nitric oxide-an endothelial cell survival factor.

Authors:  S Dimmeler; A M Zeiher
Journal:  Cell Death Differ       Date:  1999-10       Impact factor: 15.828

6.  Mechanism for phosphorylation-induced activation of the phagocyte NADPH oxidase protein p47(phox). Triple replacement of serines 303, 304, and 328 with aspartates disrupts the SH3 domain-mediated intramolecular interaction in p47(phox), thereby activating the oxidase.

Authors:  T Ago; H Nunoi; T Ito; H Sumimoto
Journal:  J Biol Chem       Date:  1999-11-19       Impact factor: 5.157

7.  Peroxisome proliferation in cultured rat hepatocytes produced by clofibrate and phthalate ester metabolites.

Authors:  T J Gray; J A Beamand; B G Lake; J R Foster; S D Gangolli
Journal:  Toxicol Lett       Date:  1982-02       Impact factor: 4.372

8.  Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy.

Authors:  I Singh; A E Moser; S Goldfischer; H W Moser
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

9.  Specificity in the action of hypolipidemic drugs: increase of peroxisomal beta-oxidation largely dissociated from hepatomegaly and peroxisome proliferation in the rat.

Authors:  P B Lazarow; H Shio; M A Leroy-Houyet
Journal:  J Lipid Res       Date:  1982-02       Impact factor: 5.922

Review 10.  Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth.

Authors:  M S Brown; J L Goldstein
Journal:  J Lipid Res       Date:  1980-07       Impact factor: 5.922

View more
  41 in total

1.  Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts.

Authors:  Wei Liu; Toni K Choueiri; Eunyoung Cho
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

2.  Antidyslipidemic and antioxidant effects of novel Lupeol-derived chalcones.

Authors:  Shishir Srivastava; Ravi Sonkar; Sunil Kumar Mishra; Avinash Tiwari; Vishal M Balaramnavar; Vishal Balramnavar; Snober Mir; Gitika Bhatia; Anil K Saxena; Vijai Lakshmi
Journal:  Lipids       Date:  2013-08-14       Impact factor: 1.880

3.  Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Arunava Ghosh; Suresh Babu Rangasamy; Khushbu K Modi; Kalipada Pahan
Journal:  J Neurochem       Date:  2017-04-03       Impact factor: 5.372

4.  Fatigue and physical activity after myocardial infarction.

Authors:  Patricia B Crane; Willie M Abel; Thomas P McCoy
Journal:  Biol Res Nurs       Date:  2014-07-15       Impact factor: 2.522

Review 5.  The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry.

Authors:  Faisal Alallaf; Fatima Amanullah H Nazar; Majed Alnefaie; Adel Almaymuni; Omran Mohammed Rashidi; Khalid Alhabib; Fahad Alnouri; Mohamed-Nabil Alama; Mohammad Athar; Zuhier Awan
Journal:  Open Cardiovasc Med J       Date:  2017-07-26

Review 6.  A Special Report on Changing Trends in Preventive Stroke/Cardiovascular Risk Assessment Via B-Mode Ultrasonography.

Authors:  Ankush Jamthikar; Deep Gupta; Narendra N Khanna; Tadashi Araki; Luca Saba; Andrew Nicolaides; Aditya Sharma; Tomaz Omerzu; Harman S Suri; Ajay Gupta; Sophie Mavrogeni; Monika Turk; John R Laird; Athanasios Protogerou; Petros P Sfikakis; George D Kitas; Vijay Viswanathan; Gyan Pareek; Martin Miner; Jasjit S Suri
Journal:  Curr Atheroscler Rep       Date:  2019-05-01       Impact factor: 5.113

7.  Gemfibrozil, a lipid-lowering drug, induces suppressor of cytokine signaling 3 in glial cells: implications for neurodegenerative disorders.

Authors:  Arunava Ghosh; Kalipada Pahan
Journal:  J Biol Chem       Date:  2012-06-08       Impact factor: 5.157

8.  Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Authors:  Sébastien A Felt; Gaith N Droby; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

Review 9.  Gemfibrozil, stretching arms beyond lipid lowering.

Authors:  Avik Roy; Kalipada Pahan
Journal:  Immunopharmacol Immunotoxicol       Date:  2009       Impact factor: 2.730

10.  Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Anamitra Ghosh; Avik Roy; Joanna Matras; Saurav Brahmachari; Howard E Gendelman; Kalipada Pahan
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.